Introduction
The use of prostatic-specific antigen (PSA) as a clinical marker for prostate cancer in the late 1980s has led to a significant rise in the number of men diagnosed with early prostate cancer. 1, 2 To date, the gold standard treatments for early prostate cancer comprise radical prostatectomy, external beam radiotherapy and brachytherapy. Increasing numbers of patients are choosing minimally invasive therapies for early prostate cancer such as external beam radiotherapy or brachytherapy to evade complications associated with major surgery.
Recurrent prostate cancer after radiotherapy is of a higher grade than the primary cancer in the majority of cases. 3 These men commonly have larger volume and advanced tumour stage. 4 Untreated local recurrence will usually result in the development of distant metastasis and ultimately death with a median survival of only 33 months. 5 Early detection of recurrence will render some of the patients suitable candidates for salvage treatment.
The aetiology of prostate cancer cell resistance to ionising radiation remains unclear. Theories of tumour resistance to radiotherapy include ineffective cell kill, pre-existing radioresistant clones, inadequate tumour localisation and de novo tumour development. 6, 7 Historically, salvage prostatectomy was the main treatment option for those patients; however, it is a technically challenging operation with considerable comorbidities. 8, 9 In the last decade, cryosurgery has reemerged as an attractive minimally invasive alternative option.
In this article, we review the position of cryotherapy in recurrent prostate cancer and compared the outcome with salvage prostatectomy in terms of cancer control and comorbidities.
Evolution and key innovations of prostate cryosurgery
The first physician to use cold to treat cancer was Dr James Arnott from Brighton, UK, between 1845 and 1851. 10 He used a mixture of ice and saline to reduce morbidity, especially pain, of women with advanced uterine and breast cancer. Solid carbon dioxide became widely used to treat various dermatological diseases in the early 20th century.
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After World War II, liquid nitrogen became commercially available and was used by Allington in the 1950s to treat superficial skin conditions. 12 Cooper and Lee 13 from New York designed the first liquid nitrogen freezing probe in 1961 capable of delivering liquid nitrogen to deep tissues achieving a temperature of À1901C.
The first prostate cryosurgery was performed by Gonder et al 14 in 1966 using a single 26Fr transurethral liquid nitrogen probe to treat bladder outlet obstruction from enlarged prostate. Complications were common, particularly urethral sloughing and rectal fistula due to lack of proper monitoring.
Flocks et al 15 modified the procedure in an attempt to reduce comorbidities. They used the open perineal approach and directly applied a flat cryoprobe. Control of the cryoablation was entirely visual. Although they managed to reduce urethral sloughing rates, a significant number of their patients experienced rectal fistula and incontinence.
In 1974, Megalli et al 16 were the first to use a closed perineal approach using a single 18Fr liquid nitrogen probe. The probe had to be repositioned several times during the procedure in order to achieve adequate freezing of the prostate and any suspected extraprostatic tumour spread. The procedure was monitored by rectal palpation. This technique avoided the morbidities of open incision and resulted in less urethral sloughing.
Complication rates remained significant due to the shortcoming of precise probe placement and monitoring the iceball. This resulted in abandonment of cryosurgery for prostate cancer.
The most significant development which led to the resurgence of interest in cryosurgery, was the introduction of real-time transrectal ultrasound-guided placement of the probes and continuous monitoring of the iceball progression by Onik et al 17 in 1993. The sound waves reflect off the frozen/unfrozen interface and appear as an advancing hyperechoic rim with anechoic shadow behind. 18 One of the limitations of ultrasound is the inability to provide information about the temperature distribution within the iceball. The introduction of thermosensors by Lee et al 19 in 1994 allowed the surgeon to monitor the temperature of the iceball precisely. This resulted in a more efficient freeze and significant rise in success rates. 20 Another key advance of modern cryosurgery was urethral mucosa protection by a warming catheter in 1995 which led to a major reduction in sloughing and incontinence rates. 20, 21 In 1996, Endocare, Inc., Irvine, CA. introduced the multiprobe high-pressure argon-helium system (Cryocaret) exploiting the Joule-Thompson effect. This replaced the (Accuprobet) liquid nitrogen system. The new system is quite compact, responds rapidly to user input and is able to create an iceball faster with steeper internal temperature gradients than the liquid nitrogen systems. 22 Tatsutani et al 23 conducted in vitro experiments with cultured prostate cancer cells and showed that temperatures of À401C or below are required for complete eradication of the cancer cells and that double freeze is more lethal than single freeze. This persuaded many urologists to modify their cryotherapy techniques leading to improved outcome in terms of PSA levels and negative biopsy rates. 24 In the late 1990s, Galil Medical introduced the third generation (SeedNett) system using ultra-thin 17-gauge needle probes. This is designed to produce higher resolution freezing and more uniform coverage of the prostate; however, more needles are required to freeze the entire prostate. To date, there has been one study with the SeedNett system with short-term follow-up. 25 The results are encouraging, but longer follow-up is required to draw firm conclusions.
In 2003, Endocare produced the fourth generation (Cryocaret CS) system with integrated biplaner ultrasound, which allows intraoperative real-time planning. This new system is designed to simplify the procedure and allow more flexibility. Both third and fourth generation systems have incorporated treatment software that enables surgeons to preset end point temperatures.
Technical considerations of salvage cryoablation
There are a few technical aspects that need to be discussed in relation to salvage cryotherapy. Complications associated with salvage cryotherapy are higher than primary cases. 26, 27 The tissues surrounding the prostate are likely to have poor vascular circulation and hence limited healing abilities post radiotherapy. 28 Therefore, freezing must be stopped once the leading edge of the iceball has reached the capsule of the prostate. 29 If the target temperature of À401C is not achieved, then you can either hold the freezing for longer periods or perform an additional freeze/thaw cycle. 20 Some surgeons inject 30-50 ml of sterile saline into the Denonvillier's fascia in order to separate the rectum and prostate and hence facilitate more adequate freezing posteriorly. 30 Other surgeons have found that 3 months androgen deprivation preoperatively can increase the distance between the anterior rectal wall and the posterior prostatic capsule by few millimetres 29 in addition to the overall reduction in prostate size.
In patients who had undergone brachytherapy, the seeds can mimic the cryoprobe ultrasonically. Therefore, in this group of patients, probe placing is slightly challenging. If you view the prostate in the longitudinal section, you can easily differentiate between the seeds and the probes.
Lastly, insertion of the cryoprobe (particularly the 17 gauge needle) might be encountered with some resistance due to fibrosis.
Comparison between salvage cryotherapy and salvage radical prostatectomy
There has not been any prospective randomised controlled trial comparing the two treatment modalities. Although direct comparison is less accurate due to variability in patient groups, follow-up length and definition of biochemical failure, it does have good value. In addition, consistency of findings by more than one investigator increases the validity of conclusions.
Using the internet, we searched MEDLINE and EMBASE libraries for articles published since 1990 using Many different definitions for biochemical failure have been used, using either a threshold or consecutive rises in PSA level. Biopsy after cryotherapy is not routinely carried out and should not be considered a standard for assessment due to problems of patients' selection and low sensitivity.
A total of 26 articles potentially met the criteria. In all, 13 papers were considered repeat publications and the most up-to-date articles were used.
Oncological outcome
With technological advancements, salvage cryosurgery has matched radical prostatectomy in terms of cancer control (Table 1) , although longer follow-up is required before ultimate conclusions are made.
Bales et al 26 published the first salvage cryosurgery experience in 1995 before the introduction of new techniques and equipments. Hence, the 12 months bDFS was unsurprisingly only 14%.
Pisters et al 27 reported the largest series (n ¼ 150). They changed from single freeze to double freeze technique after the 71st case. This resulted in a significant improvement in the bDFS from 35 to 56%, respectively. Chin et al 33 used only three thermosensors. Most of their 118 patients were high risk (60% were T3 and T4, 40% had Gleason 8-10 and more than 50% had PSA 410).
Han et al
25 described the preliminary third-generation cryosurgery experience. In this multicentre study, 18 of the 106 treated patients were salvage. The initial report is optimistic. The longest data were presented by Bahn et al. 34 At 7 y, 59% of the patients were biochemically disease-free.
The bNED rates following salvage radical prostatectomy ranged between 23 and 50% 8, 9, [35] [36] [37] [38] at different follow-up periods. Men with positive surgical margins (15.3-70%) and seminal vesicles involvement (40-50%) had higher biochemical failure rates. 8, [35] [36] [37] [38] Other prognostic factors include bladder neck invasion, preoperative PSA level and tumour cells deoxyribonucleic acid (DNA) ploidy. 8, 9 The largest and the longest follow-up series was by Amling et al. 9 They followed up 108 patients for 10 y, achieving a satisfactory 43% bNED.
Pontes et al 37 reported that only 23% of their patients were biochemically disease-free. Needless to say, 70% of the patients had positive surgical margin and 77% had pathological stage C or greater.
Morbidity
Complication (Table 2) rates following cryosurgery have declined significantly with better monitoring equipments and modification of technique. Urinary incontinence rates have declined from 95% 26 to 8%. 34 The rates of incontinence have not changed after salvage prostatectomy despite modification of surgical technique ranging from 10 to 58%. 8, 36 The most serious and challenging complication of cryotherapy is rectourethral fistula that is rarely seen nowadays. Between 0 and 10% of men had rectal injuries during salvage prostatectomy. The majority of these Salvage cryosurgery S Ahmed et al injuries were managed successfully with primary repair. 8, [35] [36] [37] [38] Impotence is common postcryosurgery, 25-27 although most men suffer from a degree of erectile dysfunction prior to salvage therapy perhaps owing to previous pelvic irradiation. 39 The majority of prostatectomy series have not documented the rates of impotence.
The mean blood loss following salvage prostatectomy was from 1000 to 1650 ml per patient. 35, 36, 38 Amling et al 9 reported that 43% of their patients required transfusion post-operatively.
There were a total of four immediate postoperative mortalities reported in both series. Three of the deaths were due to pulmonary embolism 8, 26, 37 and the other case was considered to be the result of anaesthetic complications. 37 
Conclusions
The recent technological advances and technical refinements of cryosurgery account for the higher efficacy and safety in the recent studies.
Cryosurgery is a feasible choice as salvage therapy and should be offered as a treatment option to patients with localised prostate cancer recurrence postradiotherapy. It is less invasive than salvage radical prostatectomy and causes fewer complications except for sexual impairment. Salvage cryosurgery S Ahmed et al
